January 20, 2010

American Conference Institute’s 7th National Conference on Life Sciences IP Due Diligence

Factoring Recent Developments in Life Sciences IP Case Law, Pending Patent Reform and Follow-on Biologics Legislation Into your Due Diligence Analysis

Overview

Washington, D.C., partner Mercedes Meyer, presented in a panel at the American Conference Institute’s 7th National Conference on Life Sciences IP Due Diligence, January 20, 2010, in New York.  Her co-panelists were Paul Carango of Endo Pharmaceuticals and John Li of Novartis Biologics.  Her presentation, “Factoring Recent Developments in Life Sciences IP Case Law, Pending Patent Reform and Follow-on Biologics Legislation Into your Due Diligence Analysis,” covered recent court decisions and legislative proposals relating to patent law and follow-on biologics , and how these will affect analyses undertaken during IP due diligence, particularly for pharmaceutical, biotechnology, and medical device companies. 

Services and Industries

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.